Bladder Cancer

The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.

Kristen R. Scarpato, MD, MPH, discusses what level of evidence is necessary to shift the standard of care in BCG-naive NMIBC.

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting.

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Enrollment in the ongoing pivotal QUILT-2.005 trial has now reached 85%.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

The phase 2 study is looking to evaluate nadofaragene firadenovec in combination with the investigational light-activated small molecule TLD-1433 (Ruvidar).

Tom Jayram, MD, discusses the phase 2 SURF302 trial of TYRA-300, a FGFR3-selective inhibitor for FGFR3-altered LG-IR-NMIBC.

Fed Ghali, MD, highlights simulated outcomes of the EV-302 trial when adjusting for use of maintenance avelumab in the control arm.

The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC.

The code, J9282, went into effect on January 1, 2026.

Ilaha Isali, MD, MSc, identifies major unresolved gaps in sex-specific bladder cancer research.

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

The review highlights the role of sex chromosome biology, particularly genes on the X chromosome that escape inactivation.

The combination yielded significant improvements in event-free survival, overall survival, and pathologic complete response rates vs neoadjuvant chemotherapy.

The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months.

Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.

Abhishek Srivastava, MD, discusses the potential impact that UGN-103 might have on the treatment landscape for LG-IR-NMIBC.

"In my experience, when a treatment is well-tolerated and given on a predictable schedule, patients are more likely to adhere to therapy and remain engaged in long-term follow-up," Chauhan writes.